Reactive oxygen species up-regulate p53 and puma; A possible mechanism for apoptosis during combined treatment with trail and wogonin

British Journal of Pharmacology

Volumn 157, Issue 7, 2009, Pages 1189-1202

  Lee, Dae Hee ^a   Rhee, Juong G ^b   Lee, Yong J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; DNA damage; P53; Puma; ROS; TRAIL; Wogonin

Indexed keywords

ACETYLCYSTEINE; ACTIN; CASPASE 3; CASPASE 3 INHIBITOR; CASPASE 8; CASPASE 8 INHIBITOR; CASPASE 9; CASPASE 9 INHIBITOR; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BAX; PROTEIN P53; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WOGONIN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL STRAIN HCT116; CELL STRAIN LNCAP; CELL SURVIVAL; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG POTENTIATION; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL LINE, TUMOR; DNA DAMAGE; DRUG SYNERGISM; ENZYME ACTIVATION; FLAVANONES; GENE KNOCKDOWN TECHNIQUES; HISTONES; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 70350346849     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00245.x     Document Type: Article

References (42)

1. Albano JD, Ward E, Jemal A, Anderson R, Cokkinides VE, Murray T et al. (2007). Cancer mortality in the United States by education level and race. J Natl Cancer Inst 99: 1384-1394
2. Baumann S, Fas SC, Giaisi M, Müller WW, Merling A, Gülow K et al. (2008). Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCgamma1-and Ca2+-dependent apoptosis. Blood 111: 2354-2363
3. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ (2001). Phos-phorylates histone H2A.X in response to DNA double-strand breaks. J Biol Chem 276: 42462-42467
4. Cariello NF, Beroud C, Soussi T (1994). Database and software for the analysis of mutations at the human p53 gene. Nucleic Acids Res 22: 3450-3459
5. Chen YC, Shen SC, Lee WR, Lin HY, Ko CH, Shih CM et al. (2002). Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21Cip1 protein in hepatocellular carcinoma cells SK-HEP-1. Arch Toxicol 76: 351-359
6. Chi YS, Cheon BS, Kim HP (2001). Effect of wogonin, a plant flavone from Scutellaria radix, on the suppression of cyclooxygenase-2 and the induction of inducible nitric oxide synthase in lipo-polysaccharide-treated RAW 264.7 cells. Biochem Pharmacol 61: 1195-1203
7. Chow JM, Huang GC, Shen SC, Wu CY, Lin CW, Chen YC (2008). Differential apoptotic effect of wogonin and nor-wogonin via stimulation of ROS production in human leukemia cells. J Cell Biochem 103: 1394-1404
8. Chung H, Jung YM, Shin DH, Lee JY, Oh MY, Kim HJ et al. (2008). Anticancer effects of wogonin in both estrogen receptor-positive and-negative human breast cancer cell lines in vitro and in nude mice xenografts. Int J Cancer 122: 816-822
9. Davis W Jr, Ronai Z, Tew KD (2001). Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmacol Exp Ther 296: 1-6
10. Fas SC, Baumann S, Zhu JY, Giaisi M, Treiber MK, Mahlknecht U et al. (2006). Wogonin sensitizes resistant malignant cells to TNFalpha-and TRAIL-induced apoptosis. Blood 108: 3700-3706
11. Fiers W (1991). Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 285: 199-212
12. Gaiddon C, Moorthy NC, Prives C (1999). Ref-1 regulation the trans-activation and pro apoptotic functions of p53 in vivo. EMBO J 18: 5609-5621
13. Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC et al. (2004). TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 64: 8502-8506
14. He Q, Huang Y, Sheikh MS (2004). Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and-deficient cells. Oncogene 23: 2554-2558
15. Jaruga P, Zastawny TH, Skokowski J, Dizdaroglu M, Olinski R (1994). Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Lett 341: 59-64
16. Kim YH, Lee YJ (2007). TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. J Cell Biochem 100: 998-1009
17. Kim KM, Song JJ, An JY, Kwon YT, Lee YJ (2005). Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. J Biol Chem 280: 41047-41056
18. Kim SC, Park SS, Lee YJ (2008). Effect of UV irradiation on colorectal cancer cells with acquired TRAIL resistance. J Cell Biochem 104: 1172-1180
19. Lee DH, Kim C, Zhang L, Lee YJ (2008). Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells. Biochem Pharmacol 75: 2020-2033
20. Lee WR, Shen SC, Lin HY, Hou WC, Yang LL, Chen YC (2002). Wogonin and fisetin induce apoptosis in human promyeloleukemic cells, accompanied by a decrease of reactive oxygen species, and activation of caspase 3 and Ca(2+)-dependent endonuclease. Biochem Pharmacol 63: 225-236
21. Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331
22. Li DR, Hou HX, Zhang W, Li L (2003). Effects of wogonin on inducing apoptosis of human ovarian cancer A2780 cells and telomerase activity. Ai Zheng 22: 801-805
23. Locksley RM, Killeen N, Lenardo MJ (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501
24. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T (2004). Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23: 6261-6271
25. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y et al. (1993). Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809
26. Olive PL, Banath JP (1990). Durand RE Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the 'comet' assay. Radiat Res 122: 86-94
27. Oren M (1999). Regulation of the p53 tumor suppressor protein. J Biol Chem 274: 36031-36034
28. Pei Z, Chu L, Zou W, Zhang Z, Qiu S, Qi R et al. (2004). An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 39: 1371-1381
29. Roos WP, Kain B (2006). DNA damage-induced cell death by apopto-sis. Trends Mol Med 12: 440-450
30. Shankar S, Srivastava R (2004). Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 7: 139-156
31. Shankar S, Srivastava RK (2007). Involvement of Bcl-2 family members, phosphatidylinositol 3′-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in Prostate Cancer. Inter J Oncol 30: 905-918
32. Shieh SY, Ikeda M, Taya Y, Prives C (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334
33. Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S et al. (2003). Interferon-a sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kB inactiva-tion. Oncogene 22: 1653-1662
34. Singh SV, Srivastava SK, Choi S, Lew KL, Antosiewicz J, Xiao D et al. (2005). Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem 280: 19911-19924
35. Tai MC, Tsang SY, Chang LY, Xue H (2005). Therapeutic potential of wogonin: anaturally occurring flavonoid. CNS Drug Rev 11: 141-150
36. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M (2006). Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160: 1-40
37. Wang S, El-Deiry WS (2003). Requirement of p53 targets in chemosen-sitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci 100: 15095-15100
38. Wang W, Guo Q, You Q, Zhang K, Yang Y, Yu J et al. (2006). Involvement of bax/bcl-2 in wogonin-induced apoptosis of human hepatoma cell line SMMC-7721. Anticancer Drugs 17: 797-805
39. Yang X, Fraser M, Moll UM, Basak A, Tsang BK (2006). Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 66: 3126-3136
40. Yee KS, Vousden KH (2005). Complicating the complexity of p53. Carcinogenesis 26: 1317-1322
41. Yoo J, Park SS, Lee YJ (2008). Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells. J Cell Biochem 104: 1636-1646
42. Yu JQ, Liu HB, Tian DZ, Liu YW, Lei JC, Zou GL (2007). Changes in mitochondrial membrane potential and reactive oxygen species during wogonin-induced cell death in human hepatoma cells. Hepatol Res 37: 68-76